PhRMA campaign touts Part D positives

Share this article:
PhRMA campaign touts Part D positives
PhRMA campaign touts Part D positives
PhRMA launched a national TV ad campaign aimed in part at dissuading congressional Democrats from tampering with the Medicare Part D prescription drug benefit to allow the government to negotiate drug prices.

The ad celebrates the successes of Medicare Part D, and asks viewers to call 202-224-3121 and “tell Congress we need quality affordable healthcare coverage for every American.”

“All across America, over 26 million seniors have signed up for Medicare drug coverage, choosing a private plan that fits their needs, and saving an average of $1,200.00 a year on their prescription medicine,” says the ad's narrator. “And with competition holding down costs, taxpayers are saving billions. The Medicare benefit is working, and seniors are happy.”

According to a PhRMA release, the campaign touts “the importance and success of free-market initiatives such as [Medicare Part D].” The “free-market” elements of Medicare Part D – in particular, a policy provision barring Medicare from negotiating drug prices with manufacturers – have been challenged anew by congressional Democrats.

Two bills introduced in Congress last January, one in the House (H.R.684) and one in Senate (S.330), by Rep. Robert Berry (D-AR) and Sen. Richard Durbin (D-IL), respectively, would empower government officials to “negotiate with pharmaceutical manufactures with respect to the purchase price of covered part D drugs.”
Share this article:

Email Newsletters

More in News

Meaningful use not linked to quality: study

Meaningful use not linked to quality: study

A recent study of physicians found no correlation between following EHR meaningful use requirements and providing consistently higher quality of care.

Lilly Q1 sales dip

Lilly Q1 sales dip

US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...